Trending Now
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) Gives Updates Of Its Ongoing 4-Year Phase...
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) has provided an update to its ongoing phase 1/2 valoctocogene roxaparvovec study results. The study was evaluating the investigational gene...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Immunomedics Inc. (NASDAQ:IMMU) Reports Encouraging Results from Pivotal Phase 2 TROPHY...
Immunomedics Inc. (NASDAQ:IMMU) has announced promising results from group 1 of its cisplatin-eligible patients in the Phase 2 TROPHY U-01 Trodelvy study in metastatic...
MAKE IT MODERN
LATEST REVIEWS
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Appoints a New Chief Financial Officer
Adaptive Biotechnologies Corp (NASDAQ: ADPT) has appointed a new chief financial officer (CFO). Tycho Peterson, who will fill the role, has decades of experience...
MAKE IT MODERN
PERFORMANCE TRAINING
Sesen Bio (NASDAQ: SESN) Partners With Eczacibasi Pharmaceuticals to Commercialize Vicineum In Turkey
Sesen Bio (NASDAQ: SESN) has entered a licensing agreement with Eczacibasi Pharmaceuticals Marketing for commercialization and registration of Vicineum in BCG unresponsive non-muscle invasive...
Annovis Bio (ANVS) Reports Significant Clinical Improvements with Buntanetap in Parkinson’s Disease Patients
In recent trading, Annovis Bio, Inc. (NYSE: ANVS) witnessed a notable surge in its stock value, closing at $9.28, a striking 76.09%...
OSI Systems, Inc. (NASDAQ:OSIS) Bags $5 Million Order For The Supply Of Baggage Screening...
The commonwealth government of Australia awarded an order worth $5 million to OSI Systems, Inc. (NASDAQ:OSIS). As per the terms of the contract, OSI’s...
Intellia Therapeutics Inc. (NASDAQ: NTLA) Receives MHRA Approval To Amend Phase I NTLA 2001...
Intellia Therapeutics Inc. (NASDAQ: NTLA) has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has given approval for amendment of protocol...
Moderna Inc (NASDAQ: MRNA) Demonstrates Improved Immune Response In Adolescents In Phase 2/3 Clinical...
Moderna Inc (NASDAQ: MRNA) demonstrated the safety of its COVID-19 vaccine in adolescents.
The company conducted a phase 2/3 clinical trial of its COVID-19 vaccine...
MAKE IT MODERN
